GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca Pharma India Ltd (BOM:506820) » Definitions » ROIC %

AstraZeneca Pharma India (BOM:506820) ROIC % : 37.75% (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Pharma India ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. AstraZeneca Pharma India's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was 37.75%.

As of today (2024-06-09), AstraZeneca Pharma India's WACC % is 8.71%. AstraZeneca Pharma India's ROIC % is 41.03% (calculated using TTM income statement data). AstraZeneca Pharma India generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


AstraZeneca Pharma India ROIC % Historical Data

The historical data trend for AstraZeneca Pharma India's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Pharma India ROIC % Chart

AstraZeneca Pharma India Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.57 37.46 22.12 42.66 39.98

AstraZeneca Pharma India Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.51 70.22 48.66 12.22 37.75

Competitive Comparison of AstraZeneca Pharma India's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Pharma India's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's ROIC % distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's ROIC % falls into.



AstraZeneca Pharma India ROIC % Calculation

AstraZeneca Pharma India's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Mar. 2024 is calculated as:

ROIC % (A: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2023 ) + Invested Capital (A: Mar. 2024 ))/ count )
=1695.11 * ( 1 - 26.43% )/( (2726.6 + 3511.421)/ 2 )
=1247.092427/3119.0105
=39.98 %

where

Invested Capital(A: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10780.283 - 2031.667 - ( 5237.195 - max(0, 3571.177 - 9327.064+5237.195))
=3511.421

AstraZeneca Pharma India's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=1825.04 * ( 1 - 27.37% )/( (0 + 3511.421)/ 1 )
=1325.526552/3511.421
=37.75 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10780.283 - 2031.667 - ( 5237.195 - max(0, 3571.177 - 9327.064+5237.195))
=3511.421

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AstraZeneca Pharma India  (BOM:506820) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, AstraZeneca Pharma India's WACC % is 8.71%. AstraZeneca Pharma India's ROIC % is 41.03% (calculated using TTM income statement data). AstraZeneca Pharma India generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. AstraZeneca Pharma India earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


AstraZeneca Pharma India ROIC % Related Terms

Thank you for viewing the detailed overview of AstraZeneca Pharma India's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Pharma India (BOM:506820) Business Description

Traded in Other Exchanges
Address
Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Its only operating segment being Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation and Autoimmunity, Neuroscience and Infection and Vaccines.

AstraZeneca Pharma India (BOM:506820) Headlines

No Headlines